Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Teva
UBS
US Department of Justice
Cantor Fitzgerald
Merck
Daiichi Sankyo
Deloitte
Boehringer Ingelheim

Generated: June 20, 2018

DrugPatentWatch Database Preview

Viiv Hlthcare Company Profile

« Back to Dashboard

Summary for Viiv Hlthcare
International Patents:863
US Patents:17
Tradenames:12
Ingredients:12
NDAs:19

Drugs and US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-001 Aug 12, 2013 RX Yes Yes 8,129,385 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-002 Aug 6, 2007 RX Yes Yes 7,576,097 ➤ Try a Free Trial Y ➤ Try a Free Trial
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes 6,667,314 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-003 Jun 9, 2016 RX Yes No 8,129,385 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RETROVIR zidovudine CAPSULE;ORAL 019655-001 Mar 19, 1987 4,833,130 ➤ Try a Free Trial
Viiv Hlthcare RETROVIR zidovudine TABLET;ORAL 020518-001 Dec 19, 1995 4,818,538 ➤ Try a Free Trial
Viiv Hlthcare RETROVIR zidovudine TABLET;ORAL 020518-002 Oct 4, 1996 4,837,208 ➤ Try a Free Trial
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 6,417,191*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-01-28
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2007-10-16
➤ Subscribe Tablets 300 mg/150 mg/300 mg ➤ Subscribe 2011-03-22
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2011-11-22
➤ Subscribe Tablets 10 mg, 25 mg and 50 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 600 mg/50 mg/300 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 600 mg/300 mg ➤ Subscribe 2007-09-27
➤ Subscribe Tablets 150 mg/300 mg ➤ Subscribe 2007-06-26
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2011-08-08
➤ Subscribe Tablets 700 mg ➤ Subscribe 2012-01-18
➤ Subscribe Oral Solution 20 mg/ml ➤ Subscribe 2012-12-27

Non-Orange Book US Patents for Viiv Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,592,368 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
8,188,271 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity ➤ Try a Free Trial
7,858,788 Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity ➤ Try a Free Trial
8,410,103 (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/052 Ireland ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
/2015 Austria ➤ Try a Free Trial PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
2015038 Lithuania ➤ Try a Free Trial PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128
C/GB99/032 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ABACAVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE INCLUDING ABACAVIR SULPHATE; REGISTERED: CH CH 55048 001 19990628; CH CH 55049 002 19990628; UK EU/1/99/112/001 19990708; UK EU/1/99/112/002 19990708
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Fuji
Moodys
Boehringer Ingelheim
Baxter
Teva
Julphar
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.